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• Advance statements 
• Advance decision to refuse treatment 
(advance directives) 
• Lasting power of attorney (durable power of 
attorney/ DPOA) 
• Mental Capacity Act, 2005 
 
Advance care planning 
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MyDirectives 
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MyDirectives 
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MyDirectives 
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• If you reach a point where treatments will 
extend your life by a few months and side 
effects are pretty serious, would you want 
doctors to stop, or continue to do all that 
could be done? 
 
Respecting Choices 
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• Shift in profile of dying – older, non-cancer 
• US – Patient Self-Determination Act, 1990 
• National End of Life Care Strategy 2008 
• National End of Life Care Programme (NEoLP) 
• National End of Life Care Intelligence Network 
(NEoLCIN) 
 
 
Context 
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• Supporting People to Live and Die Well 
• ‘Routes to Success’ guidance 
• Training and development 
• Care assessment, support planning and 
personalization processes 
• Holistic care – socio-legal, relationships, 
finances 
 
Social care role 
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• Less hospitalisation in last year/ 3 months 
• Fewer marginal, aggressive medical interventions  
• Earlier accessing of hospice/ palliative care 
• Better quality of life at end of life   
• Reduced stress and burden for caregivers 
• Fewer hospital deaths 
• Reduced depression/ anxiety in bereaved 
caregivers  
• Greater satisfaction with end of life care 
 
 
 
 
Benefits 
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Study aims 
• Map what is known about the economic case 
for ACP 
• Explore literature for evidence on costs, risks 
and outcomes  
• Model the economic (and other) 
consequences of ACP for a cohort of older 
decedents 
• Clarify the limitations of available evidence for 
economic evaluation 
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What does the literature say 
about cost effectiveness? 
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• Two early RCTs in US = no reduction in costs 
(Schneiderman et al., 1992; Teno et al., 1997) 
However cost benefits found in …  
• ‘Let Me Decide’ in care homes (Molloy et al., 
2000) 
• High and medium spending areas in US 
(Nicholas et al., 2011) 
Findings mixed 
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• 104 million on 1.8 billion by reducing emergency 
admissions and length of stay (NAO/ RAND, 2008) 
• £300 million through achievable 25% reduction in 
hospital deaths (Balance of Care Group, 2008)  
• 10% unnecessary admissions, case note review of 
100 decedents (Ahearn et al., 2013)  
• 93 care home residents dying in UK hospital over 
6 months, 40% died within 24 hrs of admission 
(Ong et al., 2011)  
Scope for savings 
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Baker et al., 2012 
• Advance planning initiative with case 
managed, intensive community support 
• Cost of additional staffing = £125,000 
• Savings from reduced unplanned 
hospitalization = £144,000 
• No other costs considered 
• Small, single site N=96 participants (matched), 
15 decedents 
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Abel et al., 2012 
• Decedents known to hospice in 2.5 year period 
• N= 969 (550, with ACP) 
• Hospital deaths: ACP = 11%, no ACP = 26%  
• Hospital costs last year: ACP = £8657, no ACP = 
£14,310 
• Hospital deaths national average = 51%  
• Single site, in care of hospice, mostly cancer 
patients, only hospital costs considered 
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Modelling 
• Modelling useful where empirical evidence is 
limited, unclear or complex  
• Can explore and change assumptions 
• Simple decision model for cohort of people 
age 65+ at end of life (and 6-12 months after 
death for caregivers) 
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What proportion have an ACP? 
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US estimates 
• < 33% - general population, various surveys, 
reported by Stein and Fineberg, 2013 
• 90% - Respecting Choices (Hammes et al., 
2010) 
• 76% - Bischoff et al. 2013, HRS n=4399 
decedents, mean age 82.6 
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UK estimates 
• 12% age 75+ with advance decision, 5% all 
ages (BSA, 2013) 
• 52% decedents known to UK hospice with a 
recorded place of death in records (Abel et al., 
2013) 
• 15%-62% increase in recorded advance care 
planning discussions for people on end of life 
register, evaluation of ‘Going for Gold’ 
accredited GP surgeries  
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ACP and place of death 
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Barriers 
• Not practical (e.g. no primary caregiver) 
• Late recognition  
• Clinical need (challenges of prognosis, complex 
symptom management, comorbidities) 
• Physicians may be unaware of ACP/ lack training  
• Family may have opposing preferences 
• Validity and applicability of ACP (e.g. may be too 
vague or specific for circumstances) 
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• 37% with treatment limiting advance directive 
vs 47% with no ACP (Nicholas et al., 2011)  
• 39% with any ACP vs 49% with no ACP 
(Bischoff et al., 2013)  
• 38% (of those needing decision making and 
lacking capacity) with advance directive 
and/or DPOA vs 53% with neither (Silveira et 
al., 2010) 
Hospital death 
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Associated costs 
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NEoLCP Cohort Model 
Average cost health and social care last days in community 
(weighted by deaths in each trajectory for 2009) = £1123 
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• Hospice at Home (West Kent) - £1200 
• Royal Marsden H2H – approx £1365 
• The DALE service (to enable facilitated 
discharge to die at home) - £2,800 
• NEoLCIN, What We Know Now, 2012 - £2,506 
(£1415 - £2800) 
 
 
 
Episode ending  
in death in community 
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Marie Curie  
‘Delivering Choice’ 
Includes day care, night care, ambulance discharge, district 
nurses, registered, after hours paramedic, hospice services, 
health care assistant, social service assessment, home care, 
equipment.  
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• Model very sensitive to these costs  
• Build into existing processes (e.g. dementia 
diagnosis) 
• Special initiatives – ‘complex interventions 
were found to result in an increased frequency 
of out of hospital and out of ICU care’   
(Brinkman-Stoppelenburg et al., 2014) 
 
 
Facilitation of ACP costs 
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• Costs for family caregivers omitted from cost 
evaluations (SCIE, 2013; Dumont et al., 2010)  
• ‘Bedside’ care even if in hospital or residential 
care 
• Caregivers at end of life are especially negatively 
impacted (Williams et al., 2013)  
• But potential benefits in reduced anxiety/ 
depression and increased satisfaction (Detering 
et al., 2010) 
 
 
Caregiver costs 
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Thank you! 
 
For further information email Josie Dixon: 
j.e.dixon@lse.ac.uk  
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